1. NIH/NCI: First human trials of a preventive human papillomavirus cervical cancer vaccine (HPV 16). This virus-like particle (VLP) vaccine was the progenitor of the HPV vaccine (Gardasil) recently licensed by the FDA, & of a second vaccine (Cervarix).

2. VaxGen, Inc.: Lead clinical trial site in first phase III HIV vaccine trial.

3. NIH/NIAID: Lead clinical trial site for first human studies of live attenuated recombinant RSV vaccines.

4. SBL Vaccines: Established efficacy of whole cell ETEC vaccine in field trials in Guatemala & Mexico.

5. NIH/NIAID: First human trial of a recombinant dengue virus vaccine; additional trials are ongoing.

6. Avant/Microscience: Leading single dose, oral cholera (Peru-15) & typhoid vaccines (MICRO-TY/ZH9) shown to be safe & immunogenic in early Phase I/II trials performed in Baltimore & Vermont (typhoid only).

7. Salix: Multicenter clinical trials that led to licensure of Rifamixin for treatment of traveler's diarrhea.


10. Acambis/OMAI: Challenge studies evaluating ETEC vaccines demonstrated that anti-CS3 serum IgA titer is a marker for protection against strains sharing this colonization factor.

11. Merck & Co.: Lead site for the first human testing of a live-attenuated adenovirus vectored HIV vaccine.

12. NIH/NIAID: First human trial of malaria transmission blocking vaccine.
NIH/NIAID
Pre-clinical study finds that immune complexes play a role in enhanced RSV disease.

VaxGen
New recombinant anthrax vaccine (p16:101) shown to be safe & immunogenic in multi-center trials carried out in Baltimore & other U.S. cities.

IOMAI
First human trial to evaluate the protective efficacy of an ETEC vaccine delivered transcutaneously by an arm patch.

NIH/NIAID
First human trials of a live attenuated West Nile virus vaccine.

NIH/NIAID & MedImmune
First human trials of a live attenuated H5N1 A/AA avian influenza virus vaccine.

PATH/EVI
Developed and validated low-inoculum ETEC challenge model in human volunteers that enabled 2 log reduction in challenge strain while maintaining consistently high attack rates.

Merck & Co.
Lead clinical trial site for first human studies of a preventive S. aureus vaccine.

NIH/NIAID & MedImmune
First human trials of a live attenuated H9N2 A/AA avian influenza virus vaccine.

IOMAI
Phase II field study finds an ETEC vaccine delivered transcutaneously by arm patch protects travelers to Guatemala and Mexico.

CSL Limited
Principal investigators and lead site in a large multicenter trial of a pandemic H1N1 influenza vaccine.

Norovirus Vaccine Against Experimental Human Norwalk Virus Illness
This norovirus VLP vaccine provides protection against illness and infection after challenge with a homologous virus.

ACIP Appointment
Dr. Ruth Karron was appointed to the Advisory Committee on Immunization Practices.
MILESTONE NO. 1

2013

NIH-developed candidate dengue vaccine (TV003) shows promise in early-stage trial

MILESTONE NO. 2

2013

PATH Vaccine Development Program - Shigella vaccine trial

MILESTONE NO. 3

2014

World Vaccine Congress Winner
Dr. Anna P. Durbin is the World Vaccine Congress 2014 winner for “Best Academic Research Team”

MILESTONE NO. 4

2020

Pfizer mRNA COVID-19 vaccine trial begins
Dr. Kawsar Talaat is CIR site PI in this multi-site phase III trial that led to one of the first licensed COVID-19 vaccines

MILESTONE NO. 5

2020

Astra-Zeneca COVID-19 vaccine trial begins
Dr. Anna Durbin is CIR site PI in this multi-site phase II trial to test a single dose COVID-19 vaccine

MILESTONE NO. 6

2020

MILESTONE NO. 7

Lorem ipsum dolor sit amet, consectetuer adipiscing elit, sed diam.